コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 IC50 = 0.068 +/- 0.010 mg of desipramine per kilogram).
2 d 12 received a high dose (2.0x10(14) vg per kilogram).
3 0,000 US dollars) and high mass (more than 8 kilograms).
4 to about 89,000 teragrams (1 Tg is a billion kilograms).
5 nditions for the redefinition of the SI unit kilogram.
6 justed for body weight in milliliters/minute/kilogram.
7 50) of 0.087 +/- 0.012 mg of desipramine per kilogram.
8 2 weeks, at a starting dose of 0.75 mug per kilogram.
9 in patients who received a dose of 3 mg per kilogram.
10 the realization of the definition of the new kilogram.
11 h the Avogadro project, it yields calibrated kilograms.
12 red, giving a mass M = (9,982 +/- 3) x 10(9) kilograms.
13 as 36% in the cohort that received 16 mg per kilogram (15 patients had a partial response or better,
15 1.2 (P=0.01) for patients receiving 3 mg per kilogram, 2.9 (P=0.003) for those receiving 5 mg per kil
18 to receive ipilimumab at a dose of 10 mg per kilogram (475 patients) or placebo (476) every 3 weeks f
19 22 patients who received a dose of 10 mg per kilogram, 5 (23%) had a complete response, 2 (9%) had a
20 weight and ipilimumab at a dose of 3 mg per kilogram), 53% of patients had an objective response, al
21 ing >10(4) alloreplete iC9-T lymphocytes per kilogram achieved rapid reconstitution of immune respons
22 ram of daratumumab and 42 received 16 mg per kilogram, administered once weekly (8 doses), twice mont
23 xantel pamoate at a single dose of 20 mg per kilogram; albendazole at a single dose of 400 mg; or meb
28 eded for bleeding episodes (20 to 100 IU per kilogram), and group 4 received treatment in the periope
29 lower 6-minute walking distance, peak o2 per kilogram, and 1-, 3-, and 4-year survival rates (92%, 69
30 , 2.9 (P=0.003) for those receiving 5 mg per kilogram, and 3.0 (P=0.002) for those receiving 7 mg per
31 outflowing grains of mass 10(-10) to 10(-7) kilograms, and 48 grains of mass 10(-5) to 10(-2) kilogr
32 d 3.0 (P=0.002) for those receiving 7 mg per kilogram, as compared with a reduction of 0.4 in the pla
33 /regeneration power of 1,061/1,425 watts per kilogram at a 50 per cent state of charge and at minus 3
35 ravenous secukinumab (at a dose of 10 mg per kilogram) at weeks 0, 2, and 4, followed by subcutaneous
38 = 0.048), higher islet equivalents (IEQ) per kilogram body weight (P = 0.001), and total IEQ (100,000
43 nfidence level, using a low-background, 14.6-kilogram CsI[Na] scintillator exposed to the neutrino em
44 lower baseline body mass indices (weight in kilograms divided by height in meters squared) (mean, 24
45 h a body mass index (calculated as weight in kilograms divided by height in meters squared) above 25
46 ody mass index (BMI; calculated as weight in kilograms divided by height in meters squared) alone for
47 index was 30 to 42 (calculated as weight in kilograms divided by height in meters squared) and hemog
49 dy mass index (BMI) (calculated as weight in kilograms divided by height in meters squared) cut point
50 ody mass index (BMI; calculated as weight in kilograms divided by height in meters squared) for age a
51 ody mass index (BMI, calculated as weight in kilograms divided by height in meters squared) is associ
52 's change in body mass index (BMI; weight in kilograms divided by height in meters squared) is associ
53 dy mass index (BMI) (calculated as weight in kilograms divided by height in meters squared) loss and
54 he mean maximum BMI (calculated as weight in kilograms divided by height in meters squared) loss was
55 h a body mass index (calculated as weight in kilograms divided by height in meters squared) of 30 to
56 ean body mass index (calculated as weight in kilograms divided by height in meters squared) of 31, an
57 ean body mass index (calculated as weight in kilograms divided by height in meters squared) of 32.5.
58 SD) body mass index (calculated as weight in kilograms divided by height in meters squared) of 33.8 (
59 d a body mass index (calculated as weight in kilograms divided by height in meters squared) of 35 or
60 ive body mass index (calculated as weight in kilograms divided by height in meters squared) of 47.5 (
61 ody mass index (BMI, calculated as weight in kilograms divided by height in meters squared) of less t
62 ial body mass index (calculated as weight in kilograms divided by height in meters squared) over time
63 ive body mass index (calculated as weight in kilograms divided by height in meters squared) quartiles
64 dy mass index (BMI) (calculated as weight in kilograms divided by height in meters squared) threshold
65 nus control) in BMI (calculated as weight in kilograms divided by height in meters squared) was -0.41
66 SD) body mass index (calculated as weight in kilograms divided by height in meters squared) was 39.9
67 ian body mass index (calculated as weight in kilograms divided by height in meters squared) was 50.5.
69 tic body mass index (calculated as weight in kilograms divided by height in meters squared) was signi
70 ody mass index (BMI; calculated as weight in kilograms divided by height in meters squared) z score i
71 and body mass index (calculated as weight in kilograms divided by height in meters squared), age, sex
72 ody mass index (BMI; calculated as weight in kilograms divided by height in meters squared), and clin
73 es, body mass index (calculated as weight in kilograms divided by height in meters squared), and othe
74 ine body mass index (calculated as weight in kilograms divided by height in meters squared), and surg
75 and body mass index (calculated as weight in kilograms divided by height in meters squared), the odds
80 ody mass index (BMI, calculated as weight in kilograms divided by height in meters squared); fat and
81 dy mass index [BMI], calculated as weight in kilograms divided by height in meters squared, >35.0) (h
82 sity (body mass index, measured as weight in kilograms divided by height in meters squared, of >/=30
84 her body mass index (calculated as weight in kilograms divided by height in meters squared; 30.6 vs 2
85 ody mass index [BMI; calculated as weight in kilograms divided by height in meters squared] >/=85th p
86 ts (body mass index [calculated as weight in kilograms divided by height in meters squared] of 35 or
87 ody mass index (BMI [calculated as weight in kilograms divided by height in meters squared]) and colo
88 dy mass index >/=35 [calculated as weight in kilograms divided by height in meters squared]) is assoc
89 ody mass index [BMI; calculated as weight in kilograms divided by height in meters squared], menopaus
90 dy mass index, 32.2 [calculated as weight in kilograms divided by height in meters squared]; and 67.0
91 mass index (BMI; calculated as the weight in kilograms divided by the height in meters squared) and c
92 ned as a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters)
93 ho had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters)
94 having a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters)
95 and the mean body-mass index (the weight in kilograms divided by the square of the height in meters)
96 ho had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters)
97 and the mean body-mass index (the weight in kilograms divided by the square of the height in meters)
98 late the body-mass index (BMI, the weight in kilograms divided by the square of the height in meters)
99 mean baseline body-mass index (the weight in kilograms divided by the square of the height in meters)
100 tients with a body mass index (the weight in kilograms divided by the square of the height in meters)
101 ine, the mean body-mass index (the weight in kilograms divided by the square of the height in meters)
102 es and a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters)
103 women with a body-mass index (the weight in kilograms divided by the square of the height in meters)
104 P=0.64) and 2.8 (P=0.07) with the 0.5-mg-per-kilogram dose of bapineuzumab and 0.4 (P=0.62) and 0.9 (
107 alories per kilogram or grams of protein per kilogram early post-ALI diagnosis at recommended levels
108 ed interval-adjusted prophylaxis (100 IU per kilogram every 10 days to start), group 3 received treat
110 ery 2 weeks; nivolumab at a dose of 3 mg per kilogram every 2 weeks plus placebo; or ipilimumab at a
111 am of body weight every 3 weeks or 10 mg per kilogram every 2 weeks) to either a training group (182
112 followed by nivolumab at a dose of 3 mg per kilogram every 2 weeks; nivolumab at a dose of 3 mg per
113 placebo; or ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses plus placebo, unti
114 weight plus ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses, followed by nivol
115 f body weight every 2 or 3 weeks or 2 mg per kilogram every 3 weeks in patients with advanced melanom
117 ar for early but not late protein (grams per kilogram) exposure (early-exposure HR: 8.9, 95% CI: 2.3,
118 being <3.1 x 10(-5) ampere-square meters per kilogram for meter-size homogeneous magnetized boulders.
119 o-income ratio, individual intake (grams per kilogram) for each of the other 2 protein sources, body
120 kilogram of body weight per day or 4 mg per kilogram, for 3 days, followed by a standard 3-day cours
121 venous injections of 2.5 mmol gadolinium per kilogram (gadolinium-exposed group) or saline (control g
122 ith 2 and 4 mg of intravenous tariquidar per kilogram; however, the lower dose was better tolerated.
123 evaluated ipilimumab at a dose of 10 mg per kilogram in patients who had undergone complete resectio
126 s of mechanical systems ranging in size from kilogram-mass mirrors to nanoscale membranes, as well as
127 rs) was associated with more weight gain (in kilograms; men: for <5 hours, beta = 0.66, 95% confidenc
128 = 5) or with 5 or 7.5 mg of doxorubicin per kilogram (n = 5 each) and underwent dynamic small-animal
129 age annual consumption of antimicrobials per kilogram of animal produced was 45 mgkg(-1), 148 mgkg(-1
131 of iodine per milliliter (bolus of 1 mg per kilogram of body weight administered at a rate of 3 mL/s
132 et dose of 2x10(6) anti-CD19 CAR T cells per kilogram of body weight after receiving a conditioning r
133 erse events (nivolumab at a dose of 1 mg per kilogram of body weight and ipilimumab at a dose of 3 mg
134 given 25 or 50 MBq of (177)Lu-DOTA-BR96 per kilogram of body weight and were sacrificed 2, 8, 24, 48
135 istered intravenously at a dose of 10 mg per kilogram of body weight every 14 days in patients with m
136 lizumab intravenously at a dose of 10 mg per kilogram of body weight every 2 or 3 weeks or 2 mg per k
137 to receive nivolumab (at a dose of 3 mg per kilogram of body weight every 2 weeks and dacarbazine-ma
138 y to receive nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks or docetaxel at a
139 to receive nivolumab, at a dose of 3 mg per kilogram of body weight every 2 weeks, or docetaxel, at
140 with ipilimumab at a dose of 3 or 10 mg per kilogram of body weight every 3 weeks for a total of 4 d
141 zumab (at a dose of either 2 mg or 10 mg per kilogram of body weight every 3 weeks or 10 mg per kilog
143 nistered intravenously at a dose of 1 mg per kilogram of body weight every other week); the placebo-c
144 ene at a dose of 5x10(11) vector genomes per kilogram of body weight in 10 men with hemophilia B who
145 umab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in patients with advanced melano
146 tial dose of 7.5 or 9.4 mg of imetelstat per kilogram of body weight intravenously once a week until
147 tions of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching place
148 e who were receiving 0.9 mg of alteplase per kilogram of body weight less than 4.5 hours after the on
149 ls and Methods A total dose of 13.2 mmol per kilogram of body weight of each GBCA was administered in
151 ast cancer who were injected with 1.5 mL per kilogram of body weight of iohexol and imaged between 2.
152 ed 38% and 45% lower doses in milligrams per kilogram of body weight of paclitaxel and carboplatin, r
153 cutaneous dalteparin at a dose of 200 IU per kilogram of body weight once daily for 1 month followed
154 nistered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-
155 ravirsen at doses of 3 mg, 5 mg, or 7 mg per kilogram of body weight or placebo over a 29-day period.
156 to 1200), which was equivalent to 8.1 mg per kilogram of body weight per day (range, 0.6 to 16.3).
158 ed orally at a daily dose of either 2 mg per kilogram of body weight per day or 4 mg per kilogram, fo
159 mulsion providing DHA at a dose of 60 mg per kilogram of body weight per day or a control (soy) emuls
160 abidiol oral solution at a dose of 20 mg per kilogram of body weight per day or placebo, in addition
161 s received amphotericin B (0.7 to 1.0 mg per kilogram of body weight per day) and fluconazole (800 mg
162 ive to maximal doses of diazoxide (20 mg per kilogram of body weight per day) and octreotide (35 mug
163 egimen (which included 10 mg of rifampin per kilogram of body weight per day) with an intensified reg
164 -controlled trial of amitriptyline (1 mg per kilogram of body weight per day), topiramate (2 mg per k
165 19 patients), at a dose of 0.7 to 1.0 mg per kilogram of body weight per day, or itraconazole capsule
166 ancer slope factor of 25.7 per milligram per kilogram of body weight per day, this increase in arseni
167 eceived amphotericin B at a dose of 1 mg per kilogram of body weight per day; patients in group 1 wer
168 e baseline level or urine output <0.5 ml per kilogram of body weight per hour for >/=12 hours) and wa
169 enous levosimendan (at a dose of 0.2 mug per kilogram of body weight per minute for 1 hour, followed
170 n of either ularitide at a dose of 15 ng per kilogram of body weight per minute or matching placebo f
171 ving more than 0.2 mug of norepinephrine per kilogram of body weight per minute or the equivalent dos
172 vosimendan (at a dose of 0.05 to 0.2 mug per kilogram of body weight per minute) for 24 hours or plac
173 Peak oxygen consumption (milliliters per kilogram of body weight per minute) increased more in th
174 s infusion at a dose of 0.025 to 0.2 mug per kilogram of body weight per minute) or placebo, for up t
175 f two doses of exercise: 16 kilocalories per kilogram of body weight per week (KKW), or 4 KKW for 12
176 a to receive nivolumab at a dose of 1 mg per kilogram of body weight plus ipilimumab at a dose of 3 m
177 nergy deposition (constrained by the 2-W per kilogram of body weight SAR limitations) by using five s
178 se-adjusted prophylaxis (50 IU of rFIXFc per kilogram of body weight to start), group 2 received inte
179 periods: either 40 IU or 60 IU of CSL830 per kilogram of body weight twice weekly followed by placebo
182 synovial tissue at half dose (0.05 mmol per kilogram of body weight) and at full dose (0.1 mmol/kg)
183 .5, 1.0, 2.5, 5.0, 10, and 20 x 10(8) MB per kilogram of body weight) and with control nontargeted MB
184 of gadodiamide (cumulative dose, 12 mmol per kilogram of body weight) by using inductively coupled pl
185 a 2:1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab
187 (cTACE-C) or bevacizumab (cTACE-B) (5 mg per kilogram of body weight) every 2 weeks for 52 weeks.
188 eceive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks
189 ed received nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks until they had a
190 ed ALN-TTR01 (at doses of 0.01 to 1.0 mg per kilogram of body weight) in 32 patients with transthyret
191 received intravenous secukinumab (10 mg per kilogram of body weight) or matched placebo at weeks 0,
192 lar-weight heparin (100 IU of dalteparin per kilogram of body weight) or matching placebo administere
193 stered intravenously at a dose of 2.5 mg per kilogram of body weight) or matching placebo before coro
194 mab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction tri
195 -7288 (1 mg, 4 mg, 8 mg, 12 mg, or 16 mg per kilogram of body weight) or placebo, in a 3:1 ratio.
197 agonist, as an intravenous bolus (2 mug per kilogram of body weight) over a 10-minute period; this w
198 Intravenous infusion of WST11 (4 mg per kilogram of body weight) was followed by using near-infr
199 ients received a low dose (6.7x10(13) vg per kilogram of body weight), and 12 received a high dose (2
200 o receive low-dose crizanlizumab (2.5 mg per kilogram of body weight), high-dose crizanlizumab (5.0 m
202 ee intravenous infusions of ZMapp (50 mg per kilogram of body weight, administered every third day).
203 99 with gadobenate dimeglumine [0.1 mmol per kilogram of body weight, maximum dose, 20 mL]) for hepat
204 t a starting dose of 0.025 mg or 0.04 mg per kilogram of body weight, or darbepoetin once every 2 wee
205 ents: oxantel pamoate at a dose of 20 mg per kilogram of body weight, plus 400 mg of albendazole, adm
206 strength (measured in watts and newtons per kilogram of body weight, respectively) were examined in
216 pansion phase, 30 patients received 8 mg per kilogram of daratumumab and 42 received 16 mg per kilogr
217 s (0 [control] and 0.25 and 1 milligrams per kilogram of dry soil) and two CeO2 NPs concentrations (0
219 o 30 hertz, as well as up to 41.2 joules per kilogram of electrical energy per mechanical cycle, when
221 the number of aerosol particles emitted per kilogram of fuel burned and the microphysical properties
223 apable of harvesting 2.8 liters of water per kilogram of MOF daily at relative humidity levels as low
224 enerate 5.3 kilowatts of mechanical work per kilogram of muscle weight, similar to that produced by a
225 etching coiled yarns generated 250 watts per kilogram of peak electrical power when cycled up to 30 h
227 ume assessments (evaluated in milliliter per kilogram of predicted body weight [PBW]) and daily asses
229 5-1.24; and tidal volume [in milliliters per kilogram of predicted body weight]: OR, 1.12, 95% CI, 1.
230 essed in fossil energy equivalents (FEE) per kilogram of primary copper, taking into account the appl
234 standard deviation for the test, 36 mmol per kilogram of wet weight +/- 2 [range, 34-37 mmol/kg]; for
235 he projected annual C sequestration rate (in kilograms of carbon per hectare per year) from 2006 to 2
237 acturing practices) process that produced 24 kilograms of prexasertib monolactate monohydrate suitabl
239 A cutoff level of 0.72 x 10(8) CD8 cells per kilogram optimally segregated patients receiving CD8(hi)
243 (at a dose of 0.015, 0.045, or 0.075 mg per kilogram) or once monthly (at a dose of 0.225, 0.45, 0.9
244 four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence
245 ht) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses,
246 weight), high-dose crizanlizumab (5.0 mg per kilogram), or placebo, administered intravenously 14 tim
247 m of 2.5 x 10(7) total nucleated cells (TNC)/kilogram patient body weight are frequently not availabl
248 -1.10 morphine equivalents in milligrams per kilogram per 48 hours; P = .004; I2 = 17%) and that acup
249 -0.01 morphine equivalents in milligrams per kilogram per 48 hours; P = .03; I2 = 86%) and in pain im
250 , on the basis of exposure, to be 9.6 mg per kilogram per day (95% confidence interval, 6.6 to 12.5)
251 l DHA supplementation at a dose of 60 mg per kilogram per day did not result in a lower risk of physi
252 received flucytosine at a dose of 100 mg per kilogram per day for 2 weeks, and those in group 3 concu
253 pranolol was effective at a dose of 3 mg per kilogram per day for 6 months in the treatment of infant
254 ment, the regimen of 3 mg of propranolol per kilogram per day for 6 months was selected for the final
256 lo simulations supported a dose of 11 mg per kilogram per day to match the geometric mean protective
257 hat included higher-dose rifampin (15 mg per kilogram per day) and levofloxacin (20 mg per kilogram p
258 ilogram per day) and levofloxacin (20 mg per kilogram per day) for the first 8 weeks of treatment.
259 f body weight per day), topiramate (2 mg per kilogram per day), and placebo in children and adolescen
261 rates (nanograms per hour and nanograms per kilogram per hour BW) were assessed in sample age groups
262 weight-adjusted UFR (UFRBW; milliliters per kilogram per hour) across age, sex, race/ethnicity, and
265 or 1 hour, followed by a dose of 0.1 mug per kilogram per minute for 23 hours) or placebo, with the i
266 as found to be highest (~0.24 micromoles per kilogram per year) in the vicinity of the Asian source c
268 of Ceres with a core density of 2,460-2,900 kilograms per cubic metre (that is, composed of CI and C
269 e density of this outer shell is 1,680-1,950 kilograms per cubic metre, indicating a mixture of volat
272 conducted to produce the target at roughly 3 kilograms per day using small continuous reactors, extra
274 age, maternal prepregnancy body mass index (kilograms per meter squared) and other confounders, and
277 ass product (number-average molar mass 21.4 kilograms per mole) to a mixture of linear poly[7-26]cat
279 niae gen. et sp.nov., a small-bodied (4 to 5 kilograms) primate from the Iberian Miocene (11.6 millio
280 598, P < 0.001), peak oxygen consumption per kilogram (r = -0.474, P < 0.001), and 6-minute-walk dist
281 0.01-0.05) with TEE (r = 0.26-0.38), TEE per kilogram (r = 0.31-0.41), and PAL (r = 0.36-0.48) may as
282 before vector administration vs. 49.3 IU per kilogram [range, 0 to 376] after administration; P=0.004
283 ), as was factor use (mean dose, 2908 IU per kilogram [range, 0 to 8090] before vector administration
284 yretin levels at doses of 0.15 to 0.3 mg per kilogram ranged from 82.3 to 86.8%, with reductions of 5
285 Pretreatment with 1 mg of raclopride per kilogram reduced the apparent specific binding of (18)F-
286 ASP increase during exercise and peak o2 per kilogram remained independent prognostic markers (hazard
287 mg, 15 mg, 20 mg, and 30 mg of AVI-7288 per kilogram, respectively (P<0.001 with the use of the log-
289 melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recur
290 ese conditions were executed on multigram to kilogram scale to provide three key enantiopure alpha-me
292 the coprecipitation of FeSO4 and KMnO4 in a kilogram-scale continuous process, in acidic and strongl
293 s is possible by manufacturing a perfect one-kilogram sphere from a (28)Si-enriched single crystal.
296 ansfusion of >/=0.6 x 10(9) granulocytes per kilogram tended to have better outcomes than those recei
298 e volume of air samples was traceable to the kilogram via weighing of water for the calibration of th
300 e of either 130 mg or approximately 6 mg per kilogram were significantly higher than the rates among
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。